Cargando…

Aberrant splicing in human cancer: An RNA structural code point of view

Alternative splicing represents an essential process that occurs widely in eukaryotes. In humans, most genes undergo alternative splicing to ensure transcriptome and proteome diversity reflecting their functional complexity. Over the last decade, aberrantly spliced transcripts due to mutations in ci...

Descripción completa

Detalles Bibliográficos
Autores principales: Apostolidi, Maria, Stamatopoulou, Vassiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995731/
https://www.ncbi.nlm.nih.gov/pubmed/36909167
http://dx.doi.org/10.3389/fphar.2023.1137154
_version_ 1784902883480698880
author Apostolidi, Maria
Stamatopoulou, Vassiliki
author_facet Apostolidi, Maria
Stamatopoulou, Vassiliki
author_sort Apostolidi, Maria
collection PubMed
description Alternative splicing represents an essential process that occurs widely in eukaryotes. In humans, most genes undergo alternative splicing to ensure transcriptome and proteome diversity reflecting their functional complexity. Over the last decade, aberrantly spliced transcripts due to mutations in cis- or trans-acting splicing regulators have been tightly associated with cancer development, largely drawing scientific attention. Although a plethora of single proteins, ribonucleoproteins, complexed RNAs, and short RNA sequences have emerged as nodal contributors to the splicing cascade, the role of RNA secondary structures in warranting splicing fidelity has been underestimated. Recent studies have leveraged the establishment of novel high-throughput methodologies and bioinformatic tools to shed light on an additional layer of splicing regulation in the context of RNA structural elements. This short review focuses on the most recent available data on splicing mechanism regulation on the basis of RNA secondary structure, emphasizing the importance of the complex RNA G-quadruplex structures (rG4s), and other specific RNA motifs identified as splicing silencers or enhancers. Moreover, it intends to provide knowledge on newly established techniques that allow the identification of RNA structural elements and highlight the potential to develop new RNA-oriented therapeutic strategies against cancer.
format Online
Article
Text
id pubmed-9995731
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99957312023-03-10 Aberrant splicing in human cancer: An RNA structural code point of view Apostolidi, Maria Stamatopoulou, Vassiliki Front Pharmacol Pharmacology Alternative splicing represents an essential process that occurs widely in eukaryotes. In humans, most genes undergo alternative splicing to ensure transcriptome and proteome diversity reflecting their functional complexity. Over the last decade, aberrantly spliced transcripts due to mutations in cis- or trans-acting splicing regulators have been tightly associated with cancer development, largely drawing scientific attention. Although a plethora of single proteins, ribonucleoproteins, complexed RNAs, and short RNA sequences have emerged as nodal contributors to the splicing cascade, the role of RNA secondary structures in warranting splicing fidelity has been underestimated. Recent studies have leveraged the establishment of novel high-throughput methodologies and bioinformatic tools to shed light on an additional layer of splicing regulation in the context of RNA structural elements. This short review focuses on the most recent available data on splicing mechanism regulation on the basis of RNA secondary structure, emphasizing the importance of the complex RNA G-quadruplex structures (rG4s), and other specific RNA motifs identified as splicing silencers or enhancers. Moreover, it intends to provide knowledge on newly established techniques that allow the identification of RNA structural elements and highlight the potential to develop new RNA-oriented therapeutic strategies against cancer. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995731/ /pubmed/36909167 http://dx.doi.org/10.3389/fphar.2023.1137154 Text en Copyright © 2023 Apostolidi and Stamatopoulou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Apostolidi, Maria
Stamatopoulou, Vassiliki
Aberrant splicing in human cancer: An RNA structural code point of view
title Aberrant splicing in human cancer: An RNA structural code point of view
title_full Aberrant splicing in human cancer: An RNA structural code point of view
title_fullStr Aberrant splicing in human cancer: An RNA structural code point of view
title_full_unstemmed Aberrant splicing in human cancer: An RNA structural code point of view
title_short Aberrant splicing in human cancer: An RNA structural code point of view
title_sort aberrant splicing in human cancer: an rna structural code point of view
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995731/
https://www.ncbi.nlm.nih.gov/pubmed/36909167
http://dx.doi.org/10.3389/fphar.2023.1137154
work_keys_str_mv AT apostolidimaria aberrantsplicinginhumancanceranrnastructuralcodepointofview
AT stamatopoulouvassiliki aberrantsplicinginhumancanceranrnastructuralcodepointofview